HK1215025A1 - 純化的吡咯並喹啉基-吡咯烷- -二酮組合物和用於製備且使用其的方法 - Google Patents

純化的吡咯並喹啉基-吡咯烷- -二酮組合物和用於製備且使用其的方法

Info

Publication number
HK1215025A1
HK1215025A1 HK16103027.3A HK16103027A HK1215025A1 HK 1215025 A1 HK1215025 A1 HK 1215025A1 HK 16103027 A HK16103027 A HK 16103027A HK 1215025 A1 HK1215025 A1 HK 1215025A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolidine
preparing
methods
same
pyrroloquinolinyl
Prior art date
Application number
HK16103027.3A
Other languages
English (en)
Inventor
P Reed David
R Barnes Neil
C Kane John
A Lee Christopher
Chen Jian-Xie
P Redmon Martin
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of HK1215025A1 publication Critical patent/HK1215025A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK16103027.3A 2009-12-23 2016-03-16 純化的吡咯並喹啉基-吡咯烷- -二酮組合物和用於製備且使用其的方法 HK1215025A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
HK1215025A1 true HK1215025A1 (zh) 2016-08-12

Family

ID=44188284

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103027.3A HK1215025A1 (zh) 2009-12-23 2016-03-16 純化的吡咯並喹啉基-吡咯烷- -二酮組合物和用於製備且使用其的方法

Country Status (19)

Country Link
US (3) US8552192B2 (zh)
EP (2) EP3081567A3 (zh)
JP (2) JP2013515737A (zh)
KR (2) KR101669707B1 (zh)
CN (2) CN104910159A (zh)
AU (2) AU2010336533B9 (zh)
BR (1) BR112012015656A2 (zh)
CA (1) CA2785503A1 (zh)
CO (1) CO6561823A2 (zh)
HK (1) HK1215025A1 (zh)
MX (1) MX2012007259A (zh)
MY (1) MY156701A (zh)
NZ (2) NZ628087A (zh)
PH (1) PH12014500310A1 (zh)
RU (1) RU2556205C2 (zh)
SG (1) SG181927A1 (zh)
TW (3) TWI506026B (zh)
WO (1) WO2011079142A2 (zh)
ZA (1) ZA201204759B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101941970B (zh) * 2005-02-09 2013-08-21 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
CA2785503A1 (en) * 2009-12-23 2011-06-30 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
AU2012278831A1 (en) * 2011-07-07 2014-01-16 Arqule, Inc Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
US9000005B2 (en) 2012-04-23 2015-04-07 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
WO2015008221A1 (en) * 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
KR102700883B1 (ko) * 2017-08-11 2024-09-02 액투에이트 테라퓨틱스 인크. 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의 고체 형태
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4319740A1 (en) * 2021-04-07 2024-02-14 Urica Therapeutics, Inc. Urat1 inhibitor, pharmaceutical compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
US6867198B2 (en) * 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
WO2004013069A1 (en) * 2002-07-31 2004-02-12 Firmenich Sa A process for the optical resolution of a precursor of sclareolide
US20060058532A1 (en) * 2004-09-10 2006-03-16 Warren Chew Process for the scalable synthesis of 1,3,4,9-tetrahydropyrano[3,4-b]-indole derivatives
CN101941970B (zh) * 2005-02-09 2013-08-21 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
WO2009002807A2 (en) * 2007-06-22 2008-12-31 Arqule, Inc. Indolyl pyrrolidines for the treatment of cancer
EP2170870B1 (en) 2007-06-22 2014-03-05 ArQule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CA2785503A1 (en) * 2009-12-23 2011-06-30 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
US9000005B2 (en) * 2012-04-23 2015-04-07 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Also Published As

Publication number Publication date
WO2011079142A3 (en) 2011-11-24
ZA201204759B (en) 2014-03-26
CN102834097A (zh) 2012-12-19
CO6561823A2 (es) 2012-11-15
WO2011079142A2 (en) 2011-06-30
EP3081567A2 (en) 2016-10-19
EP2515904A4 (en) 2013-07-03
AU2010336533A1 (en) 2012-07-12
US20110160242A1 (en) 2011-06-30
NZ628087A (en) 2016-02-26
TW201141865A (en) 2011-12-01
PH12014500310A1 (en) 2015-09-28
KR101669707B1 (ko) 2016-10-27
SG181927A1 (en) 2012-07-30
CA2785503A1 (en) 2011-06-30
TWI506026B (zh) 2015-11-01
AU2015243015A1 (en) 2015-11-05
TWI557125B (zh) 2016-11-11
RU2012131344A (ru) 2014-01-27
US20140031551A1 (en) 2014-01-30
MX2012007259A (es) 2015-05-15
US8871933B2 (en) 2014-10-28
EP3081567A3 (en) 2016-11-16
US20160024076A1 (en) 2016-01-28
CN102834097B (zh) 2015-06-17
JP2016041712A (ja) 2016-03-31
AU2010336533B9 (en) 2015-10-08
AU2015243015B2 (en) 2017-02-02
MY156701A (en) 2016-03-15
EP2515904A2 (en) 2012-10-31
BR112012015656A2 (pt) 2016-05-10
RU2556205C2 (ru) 2015-07-10
US8552192B2 (en) 2013-10-08
TW201542546A (zh) 2015-11-16
US9499540B2 (en) 2016-11-22
TW201643163A (zh) 2016-12-16
CN104910159A (zh) 2015-09-16
JP2013515737A (ja) 2013-05-09
NZ600800A (en) 2014-10-31
AU2010336533B2 (en) 2015-09-10
KR20160121602A (ko) 2016-10-19
KR20120113760A (ko) 2012-10-15

Similar Documents

Publication Publication Date Title
IL254076A0 (en) 5-Fluoropyrimidinone derivatives, preparations containing them and methods of using them
HK1215025A1 (zh) 純化的吡咯並喹啉基-吡咯烷- -二酮組合物和用於製備且使用其的方法
ZA201006944B (en) Compositions and methods for preparing and using same
ZA201203183B (en) Sulfomethylsuccinates, process for making same and compositions containing same
PT3812360T (pt) Compostos de monoclorotrifluoropropeno e composições e métodos utilizando os mesmos
ZA201203603B (en) Lyophilization methods, compositions, and kits
IL216388A0 (en) New compounds, pharmaceutical composition and methods relating thereto
ZA201600550B (en) Compositions, methods and uses for inducing viral growth
PT2504331E (pt) Composto, novas formas desse composto, composições farmacêuticas desse composto e métodos de preparação e utilização
EP2438173A4 (en) BIOMATERIALS, COMPOSITIONS AND METHODS
EP2294198A4 (en) METHODS AND COMPOSITIONS FOR ENHANCING PLANTS
HRP20150021T1 (en) Phenanthrenone compounds, compositions and methods
EP2655372A4 (en) PYRROLOQUINOLELINELYL-PYRROLIDINE-2,5-DIONE COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME
EP2496593A4 (en) AMPHIPHILIC COMPOSITIONS AND PREPARATION METHODS USING THE SAME
HK1179519A1 (zh) 免疫原、組合物及其用途和製備方法
HK1166017A1 (zh) 引起神經突生長的組合物和方法
AU2008905185A0 (en) Methods and compositions for preparing hormone-depleted surem